Afatinib (BIBW2992)

Catalog No.S1011

Molecular Weight(MW): 485.94

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively.

Cited by 98 Publications

Nature, 2019, 571(7763):127-131

PubMed: 31243371 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001

PubMed: 31588020 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(5):638-646

PubMed: 29686424 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2013, 3(2):168-81

PubMed: 23229345 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):266

PubMed: 31215502 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):733-742

PubMed: 30787176 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):920-928

PubMed: 30872380 ( click the link to review the publication )

J Cancer, 2019, 10(9):2063-2073

PubMed: 31205567 ( click the link to review the publication )

Gynecol Oncol, 2019, 153(1):158-164

PubMed: 30630630 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28881

PubMed: 31152452 ( click the link to review the publication )

Clin Lung Cancer, 2019, 20(3):167-177

PubMed: 30885551 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0248-2

PubMed: 31171828 ( click the link to review the publication )

Front Physiol, 2019, 10:189

PubMed: 30971932 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )
Transl Oncol, 2019, 12(6):852-858

PubMed: 31030101 ( click the link to review the publication )

Oncol Rep, 2019, 41(2):1059-1066

PubMed: 30483795 ( click the link to review the publication )

Oncotarget, 2019, 10(14):1440-1457

PubMed: 30858928 ( click the link to review the publication )

Theranostics, 2018, 8(12):3176-3188

PubMed: 29930721 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2144-2155

PubMed: 30065098 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2024-2033

PubMed: 29959202 ( click the link to review the publication )

Mol Oncol, 2018, 12(6):830-854

PubMed: 29603584 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Front Oncol, 2018, 8:432

PubMed: 30345256 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1541-1550

PubMed: 30210922 ( click the link to review the publication )

Ann Thorac Surg, 2018, 105(2):363-370

PubMed: 29223420 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Biosci Rep, 2018, 38(6)

PubMed: 30420490 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8201-8209

PubMed: 30568455 ( click the link to review the publication )

J Craniomaxillofac Surg, 2018, 46(3):492-497

PubMed: 29311018 ( click the link to review the publication )

Oncotarget, 2018, 9(9):8560-8572

PubMed: 29492217 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Neoplasia, 2017, 19(12):1012-1021

PubMed: 29136529 ( click the link to review the publication )

Cancer Prev Res, 2017, 10(1):76-88

PubMed: 27756753 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 335:16-27

PubMed: 28942004 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(3):656-661

PubMed: 28756224 ( click the link to review the publication )
Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Gut, 2016, 1296-305

PubMed: 26001389 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Expert Opin Drug Deliv, 2016, 13(1):133-41

PubMed: 26371512 ( click the link to review the publication )

Mol Pharm, 2016, 13(6):2117-25

PubMed: 27169328 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(8):1708-19

PubMed: 27648360 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0146311

PubMed: 26735495 ( click the link to review the publication )

Mol Med Rep, 2016, 13(3):2338-44

PubMed: 26782932 ( click the link to review the publication )

Oncotarget, 2016, 7(28):42859-42872

PubMed: 27374095 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58038-58050

PubMed: 27487128 ( click the link to review the publication )

Gut, 2015, 10.1136/gutjnl-2014-309026

PubMed: ( click the link to review the publication )

J Thorac Oncol, 2015, 10(1):93-101

PubMed: 25384171 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-13-0951

PubMed: 25589492 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(3):375-84

PubMed: ( click the link to review the publication )

Cell Tissue Res, 2015, 359(3):799-816

PubMed: ( click the link to review the publication )

Arch Immunol Ther Exp, 2015, 10.1007/s00005-015-0330-5

PubMed: 25678473 ( click the link to review the publication )
PLoS One, 2015, 10(4):e0123623

PubMed: 25853726 ( click the link to review the publication )

Anticancer Res, 2015, 35(4):2005-8

PubMed: 25862853 ( click the link to review the publication )

J Anal Methods Chem, 2015, 2015:215128

PubMed: 26101692 ( click the link to review the publication )

Nat Commun, 2014, 5:5232

PubMed: 25366117 ( click the link to review the publication )

J Natl Cancer Inst, 2014, 106(9)

PubMed: 25214559 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(21):5423-34

PubMed: 25189483 ( click the link to review the publication )

Cancer Res, 2014, 74(1):341-52

PubMed: 24177178 ( click the link to review the publication )

Br J Cancer, 2014, 111(9):1750-6

PubMed: 25268372 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(9):1239-47

PubMed: 24971884 ( click the link to review the publication )

Histochem Cell Biol, 2014, 142(4):361-71

PubMed: 24824474 ( click the link to review the publication )

Target Oncol, 2014, 10.1007/s11523-014-0344-7

PubMed: 25341405 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Eur J Cancer, 2013, 49(6):1458-66

PubMed: 23153706 ( click the link to review the publication )

Oncogene, 2013, 32(37):4427-35

PubMed: 23045273 ( click the link to review the publication )

Cancer Sci, 2013, 104(5):584-9

PubMed: 23387505 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

PLoS One, 2013, 8(12):e84700

PubMed: 24386407 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(6):1663-71

PubMed: 22317763 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41017

PubMed: 22815900 ( click the link to review the publication )
Oncol Res, 2011, 19(10-11):471-8

PubMed: 22715590 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively.

Targets

EGFR (L858R) ^[1] (Cell-free assay)	EGFR (wt) ^[1] (Cell-free assay)	ErbB4 ^[2] (Cell-free assay)	EGFR (L858R/T790M) ^[1] (Cell-free assay)	HER2 ^[1] (Cell-free assay)
0.4 nM	0.5 nM	1 nM	10 nM	14 nM

In vitro

BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
HDLM-2	M13FcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPFTWM2OD1yLkCwOVczKM7:TR?=	NEnxPXZUSU6JRWK=
KASUMI-1	NFXGZWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlOzTWM2OD1yLkCwPVEyKM7:TR?=	NXfXcpZCW0GQR1XS
HCC2218	NX7PU3VkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\wTWM2OD1yLkCwPVg4KM7:TR?=	NWry[FhxW0GQR1XS
KARPAS-45	NVfhTFd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmr5TWM2OD1yLkCxOlcyKM7:TR?=	NFe2bY1USU6JRWK=
HSC-4	NEfn[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDOTWM2OD1yLkCxO\|Q5KM7:TR?=	M37hfnNCVkeHUh?=
CHL-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTYeIY5UUN3ME2wMlAyQDN7IN88US=>	M4LNT3NCVkeHUh?=
KY821	NF3oU\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXWN49ZUUN3ME2wMlAzODZizszN	MWHTRW5ITVJ?
NCI-N87	Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DWWGlEPTB;MD6wNlc4OyEQvF2=	M{fzcXNCVkeHUh?=
DOK	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLV[\|JOUUN3ME2wMlA{OTl2IN88US=>	MoPSV2FPT0WU
DSH1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYf4NYRiUUN3ME2wMlA{OzF2IN88US=>	NI\3TnlUSU6JRWK=
MDA-MB-175-VII	NEjQOoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwMEO0NVYh\|ryP	NW\Uc4JzW0GQR1XS
NCI-H2170	NH7mUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljpTWM2OD1yLkCzO\|I5KM7:TR?=	MXzTRW5ITVJ?
BT-474	MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrjUnZKSzVyPUCuNFQ6QDZizszN	NEnvcoxUSU6JRWK=
EFO-27	NFTsPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmj3TWM2OD1yLkC1NVgzKM7:TR?=	MnLQV2FPT0WU
NCI-H720	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVu0RnYzUUN3ME2wMlA2OzJ3IN88US=>	Ml;nV2FPT0WU
PC-14	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTBwMEW2Olgh\|ryP	NELqT3lUSU6JRWK=
EC-GI-10	MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLFW2lKSzVyPUCuNFU6OTJizszN	M{T2VXNCVkeHUh?=
KYSE-450	NYnjRmRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLV[ZVIUUN3ME2wMlA2QTd6IN88US=>	NH;LfmdUSU6JRWK=
BPH-1	NVnMdo9ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\QdWlEPTB;MD6wOVk5QCEQvF2=	NWHDU4RTW0GQR1XS
NCI-H292	M3[0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHxTWM2OD1yLkC2NFkh\|ryP	M{LsSHNCVkeHUh?=
H9	NUXqWYdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33COWlEPTB;MD6wO\|E{OiEQvF2=	NGS0[WFUSU6JRWK=
NCI-H526	Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPVTWM2OD1yLkC3PFI{KM7:TR?=	NW\WV3BqW0GQR1XS
NCI-H1623	NXPKTW5[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3mUpk6UUN3ME2wMlA5ODJ3IN88US=>	M3PJbnNCVkeHUh?=
KYSE-140	NXjrOWFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV74VmRFUUN3ME2wMlA5OzNizszN	NFHqb4dUSU6JRWK=
Ca9-22	NF\zOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\LcmlEPTB;MD6wPFM2OyEQvF2=	MmHsV2FPT0WU
AU565	MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTBwMEi1NFQh\|ryP	MW\TRW5ITVJ?
ZR-75-30	M2S3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml[xTWM2OD1yLkC5OVQ2KM7:TR?=	Mk\QV2FPT0WU
NCI-H1770	MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHmTWM2OD1yLkGwNlgh\|ryP	MYTTRW5ITVJ?
LB2241-RCC	NIK2VGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjHd\|ZHUUN3ME2wMlExQDh2IN88US=>	MVrTRW5ITVJ?
CAL-39	M1r1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4j1c2lEPTB;MD6xNVc6OiEQvF2=	M{\oUHNCVkeHUh?=
UACC-893	NEC1WYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHP0ZlRKSzVyPUCuNVE5QDVizszN	MVjTRW5ITVJ?
LU-65	NHrLd\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwMUK2N\|Mh\|ryP	NYK4R3M3W0GQR1XS
HN	NEnxUlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHHTWM2OD1yLkGzNFc4KM7:TR?=	Ml33V2FPT0WU
TI-73	M3\6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7uTJJKSzVyPUCuNVQ4OTVizszN	NEWyXpVUSU6JRWK=
KU812	Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvPU2p6UUN3ME2wMlE2PDV4IN88US=>	NIHWd5FUSU6JRWK=
SW13	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfTc\|F5UUN3ME2wMlE3OjF4IN88US=>	MkjUV2FPT0WU
BB30-HNC	M1q0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYD2NZZGUUN3ME2wMlE3PTd4IN88US=>	MkPDV2FPT0WU
HSC-2	NUD2fYwzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHiXolKSzVyPUCuNVY5OzdizszN	M1;xeXNCVkeHUh?=
BV-173	NXy2T2JqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGi3THVKSzVyPUCuNVc2QTZizszN	M2W2SHNCVkeHUh?=
CAL-27	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPWS4tKSzVyPUCuNVc3OzZizszN	NGPzdJhUSU6JRWK=
SBC-1	NGK2dI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwMUi5OVkh\|ryP	NGDpSZRUSU6JRWK=
CAL-33	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTBwMkCxPFQh\|ryP	M3nidXNCVkeHUh?=
NCI-H209	NV7XSIEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTqUlBqUUN3ME2wMlIxPDZizszN	MXjTRW5ITVJ?
COR-L105	NX\iV2JYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPTTWM2OD1yLkKxNFg1KM7:TR?=	MXXTRW5ITVJ?
HSC-3	NV75TWNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwMkGxPVgh\|ryP	Mm\pV2FPT0WU
NCI-H69	MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXi5PHR5UUN3ME2wMlIyPDVzIN88US=>	NH7ofmNUSU6JRWK=
MOLT-13	M3[4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\VXXJKSzVyPUCuNlM6PzVizszN	NVvERWVsW0GQR1XS
ML-2	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTBwMkS4NFIh\|ryP	MU\TRW5ITVJ?
IGROV-1	M321W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMkW5OVIh\|ryP	MoPyV2FPT0WU
TK10	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXNWVZKSzVyPUCuNlY4OzhizszN	M3n1OnNCVkeHUh?=
EoL-1-cell	NF:1[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTBwMk[4PVIh\|ryP	NHT2dGdUSU6JRWK=
HO-1-N-1	M4fDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{Tvd2lEPTB;MD6yO\|g2OyEQvF2=	M17EbXNCVkeHUh?=
BHY	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjndog2UUN3ME2wMlI5PjV3IN88US=>	NF\ndpNUSU6JRWK=
LU-139	MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vHNmlEPTB;MD6zNFUyKM7:TR?=	MWHTRW5ITVJ?
23132-87	M4XKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\pTWM2OD1yLkOxPVI{KM7:TR?=	MnOzV2FPT0WU
ACHN	Mkf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\ROVVKSzVyPUCuN\|E6QTRizszN	NHfPOHRUSU6JRWK=
DoTc2-4510	NH60dYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnf0TWM2OD1yLkOyNlE6KM7:TR?=	NFjCfXFUSU6JRWK=
BB65-RCC	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTPVVVxUUN3ME2wMlM1PTl\|IN88US=>	NWrQdWhzW0GQR1XS
HLE	NF23cohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXRZ41KSzVyPUCuN\|UxPDZizszN	MVfTRW5ITVJ?
HCC1419	NGTx[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkD0TWM2OD1yLkO2OFA5KM7:TR?=	NUniN3ZnW0GQR1XS
A388	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nTT2lEPTB;MD6zOlg2PyEQvF2=	MUDTRW5ITVJ?
NUGC-3	NHTJeFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTBwM{izO\|Mh\|ryP	NWLW[VlEW0GQR1XS
KYSE-180	NG\YWnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;QbXhKSzVyPUCuN\|kxQDlizszN	NFrYUHFUSU6JRWK=
TE-6	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\Kd2lEPTB;MD60NFI1PiEQvF2=	NFnJdVJUSU6JRWK=
A498	NILWZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1K0OmlEPTB;MD60NFY4PCEQvF2=	MkDGV2FPT0WU
NCI-H1648	MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2D2bmlEPTB;MD60OFE5OiEQvF2=	Mmm1V2FPT0WU
DU-145	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTJOYluUUN3ME2wMlQ1QDN\|IN88US=>	MV\TRW5ITVJ?
CW-2	NELaVolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\3PIttUUN3ME2wMlQ3QTF2IN88US=>	MkC1V2FPT0WU
A431	Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwNEiyN\|Mh\|ryP	NWnRfYZZW0GQR1XS
SAS	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwNEizPVgh\|ryP	NYLwZ5g{W0GQR1XS
NCI-H2126	M{TnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDoTWM2OD1yLkWxPVI3KM7:TR?=	MVjTRW5ITVJ?
NCI-H358	MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXj3TIlWUUN3ME2wMlU{OjFizszN	NGPDeoxUSU6JRWK=
FADU	NWHJUmJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDSNpRKSzVyPUCuOVQ1ODRizszN	MlPGV2FPT0WU
ACN	NYfjdFFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTNe5RUUUN3ME2wMlU2ODl2IN88US=>	NH3sN4VUSU6JRWK=
HCC70	NIf2OmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PmZWlEPTB;MD61O\|Y3OSEQvF2=	MlrIV2FPT0WU
NCI-H1838	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NViyXHQ5UUN3ME2wMlYxOjl7IN88US=>	NHnZRZhUSU6JRWK=
CAL-54	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjwZ2plUUN3ME2wMlYyPjJzIN88US=>	MXTTRW5ITVJ?
NCI-H1975	NXnjfXp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFj6ZWRKSzVyPUCuOlE4OjhizszN	NE\GdHhUSU6JRWK=
COR-L88	NYfoU3U5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHuTXFKSzVyPUCuOlQyOTNizszN	NHPnZnFUSU6JRWK=
CTV-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwNkSzPVIh\|ryP	NYrudZh2W0GQR1XS
EW-18	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTBwNki2PVgh\|ryP	NXXYclk1W0GQR1XS
HCC1806	M2n1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{P4eGlEPTB;MD62PVY3PiEQvF2=	NX7lNFF2W0GQR1XS
HuP-T4	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3K1VGlEPTB;MD62PVc3KM7:TR?=	M2L3SHNCVkeHUh?=
MDA-MB-361	NFrIO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTBwN{K2OlIh\|ryP	MYHTRW5ITVJ?
NCI-H1573	Moq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M32zS2lEPTB;MD63N\|Y{KM7:TR?=	NWW3dmJkW0GQR1XS
KU-19-19	MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvaV3JqUUN3ME2wMlc4PDZ2IN88US=>	NFvrNmJUSU6JRWK=
COLO-678	Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjxNYZKSzVyPUCuPFA5OzRizszN	NYf2bowxW0GQR1XS
C-33-A	NIKwR2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPNTVJ5UUN3ME2wMlgyOjl5IN88US=>	MnXJV2FPT0WU
Calu-3	NHnuUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7PfJFKSzVyPUCuPFE1OzRizszN	M4Xv[nNCVkeHUh?=
AGS	M1HpPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjwPWpKSzVyPUCuPFM3PDhizszN	MVvTRW5ITVJ?
SCC-25	MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTBwOESxO\|Eh\|ryP	NUDzT3Z3W0GQR1XS
JVM-2	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTBwOEiyPVkh\|ryP	NYPyflRNW0GQR1XS
HCE-T	NXnFNGFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmizTWM2OD1yLki4OFI5KM7:TR?=	NU\nc5RjW0GQR1XS
ES4	M1PKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PpVWlEPTB;MD65O\|g{PiEQvF2=	NWHxNIRnW0GQR1XS
EKVX	M1ztWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTFwMEGwOlQh\|ryP	NYXaN25CW0GQR1XS
D-542MG	NF3ZN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHf0VJNKSzVyPUGuNFExPjRizszN	NWrO[HpkW0GQR1XS
SW1116	NXfCT2xwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHtfodKSzVyPUGuNFEzQDdizszN	NFzBPJBUSU6JRWK=
5637	M{jVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrQbGw5UUN3ME2xMlAyPTFizszN	NI\IdZZUSU6JRWK=
HT-1376	NVntVVFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHKS3VKSzVyPUGuNFE2OTNizszN	MkDpV2FPT0WU
NB69	MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XCOGlEPTB;MT6wNlk1PSEQvF2=	NHnUdIdUSU6JRWK=
YKG-1	MlPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHj1bIpKSzVyPUGuNFU1OTlizszN	MU\TRW5ITVJ?
EW-3	NYjBeItIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M361OmlEPTB;MT6wO\|g5OyEQvF2=	NFW2b29USU6JRWK=
GCIY	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHQUo1KSzVyPUGuNFgyODRizszN	M17KOXNCVkeHUh?=
SK-MES-1	M33rR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vGcmlEPTB;MT6xNVQ5PyEQvF2=	NYLJdVNTW0GQR1XS
PANC-08-13	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfPTWM2OD1zLkG2OFE3KM7:TR?=	MV\TRW5ITVJ?
SK-NEP-1	NYX2[3RZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zySGlEPTB;MT6xO\|UyOyEQvF2=	NV7oSZNuW0GQR1XS
SW954	NFjKd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37m[mlEPTB;MT6yNFIyPCEQvF2=	M3;FdHNCVkeHUh?=
NCI-SNU-5	Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrmPFFOUUN3ME2xMlI{QSEQvF2=	MoPqV2FPT0WU
SW48	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXTTWM2OD1zLkK1OFMzKM7:TR?=	MVvTRW5ITVJ?
HT-3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnl[mY4UUN3ME2xMlI5PzV\|IN88US=>	NXPvXnhWW0GQR1XS
ETK-1	M2e2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTFwM{e0OVYh\|ryP	NEj2cItUSU6JRWK=
SCC-15	M4LhNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnpTWM2OD1zLkO5OFUyKM7:TR?=	M3fFT3NCVkeHUh?=
DU-4475	NHzxRlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUi3TlBqUUN3ME2xMlQxOTJzIN88US=>	NI\IVHRUSU6JRWK=
NB5	M2fXSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonNTWM2OD1zLkSxN\|E4KM7:TR?=	NWnnV2J1W0GQR1XS
CFPAC-1	M4KyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPxZ2lKSzVyPUGuOFI1QTNizszN	NICxZ5BUSU6JRWK=
NCI-H630	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LRWmlEPTB;MT60OVU5OiEQvF2=	MU\TRW5ITVJ?
NCI-H82	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTFwNUSwNFYh\|ryP	MVXTRW5ITVJ?
ECC10	M1jZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPuSoZKSzVyPUGuOVU{PjlizszN	M4LpN3NCVkeHUh?=
K5	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzEUJF{UUN3ME2xMlU5OzV5IN88US=>	M4rE[nNCVkeHUh?=
ME-180	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PxXWlEPTB;MT62NVA6PiEQvF2=	M1[2[HNCVkeHUh?=
KYSE-410	MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTFwNkW2O\|Ih\|ryP	MWDTRW5ITVJ?
G-401	NHv1VoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjkTWM2OD1zLk[3OFE{KM7:TR?=	NIrGUY9USU6JRWK=
TGBC24TKB	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTuTWM2OD1zLk[4NlMh\|ryP	M1:xPHNCVkeHUh?=
Detroit562	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXRWJRKSzVyPUGuO\|AyPTJizszN	M1u5ZnNCVkeHUh?=
OE19	NWjjVXBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTFwN{G1NVIh\|ryP	NIHvcINUSU6JRWK=
CAKI-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXT0bnhPUUN3ME2xMlc5OjFzIN88US=>	MmLYV2FPT0WU
TE-12	MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfFRmt3UUN3ME2xMlgxPDF2IN88US=>	M2f0eHNCVkeHUh?=
NCI-H1666	M3jBUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HLdGlEPTB;MT64NFk1QCEQvF2=	NGrFeWJUSU6JRWK=
TE-1	M3rWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTFwOEG0O\|Uh\|ryP	M{jhenNCVkeHUh?=
CAL-12T	Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTFwOEi5OFUh\|ryP	MWDTRW5ITVJ?
TE-8	M37FT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnM[ppOUUN3ME2xMlkyOzd5IN88US=>	NUK1UoMxW0GQR1XS
KYSE-270	Mny0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTJwMEK3N\|Ih\|ryP	NInuOnNUSU6JRWK=
GMS-10	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrCfI9VUUN3ME2yMlA{PTF5IN88US=>	MkKyV2FPT0WU
A2780	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjpcoJKSzVyPUKuNFYzQTRizszN	NVLlb5ZDW0GQR1XS
OMC-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTJwMEixOlkh\|ryP	NHrWPFRUSU6JRWK=
LoVo	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTJwMUC3PVch\|ryP	NWLnWnc6W0GQR1XS
PANC-03-27	NF:3R4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHRSIVpUUN3ME2yMlE3PjNzIN88US=>	MlH3V2FPT0WU
MDA-MB-157	NEnKPXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\TPGlEPTB;Mj6yNVgzQCEQvF2=	M4XlWHNCVkeHUh?=
CaR-1	NGLPTVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jDeWlEPTB;Mj6yPFI5OSEQvF2=	M3LQ[3NCVkeHUh?=
769-P	MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnjTWM2OD1{LkK5NFM4KM7:TR?=	NWHWVJl7W0GQR1XS
NB7	MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rqWWlEPTB;Mj6yPVY4PiEQvF2=	NHzMUZlUSU6JRWK=
MKN7	M{HIcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTJwM{WzN\|Uh\|ryP	NHrRU3NUSU6JRWK=
NCI-H1048	M4H0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXKTWM2OD1{LkS5NVU5KM7:TR?=	M4\WTnNCVkeHUh?=
RCM-1	M1LLR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\ITWM2OD1{LkWyPVM5KM7:TR?=	M1zkUnNCVkeHUh?=
HT55	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH:2NYxKSzVyPUKuOVc{QCEQvF2=	MljBV2FPT0WU
HCC1569	M2\mc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzFTHZKSzVyPUKuOVgzQTdizszN	NGPmR4hUSU6JRWK=
LXF-289	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vlbmlEPTB;Mj62N\|U3PSEQvF2=	NEDqUVRUSU6JRWK=
OVCAR-3	MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLCRWx7UUN3ME2yMlY4OTZ5IN88US=>	MWjTRW5ITVJ?
TE-10	M3vGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTJwNkiwO\|gh\|ryP	NWnZXGJuW0GQR1XS
SNU-C2B	M1P2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PMRWlEPTB;Mj62PFYyPiEQvF2=	NXrVW5lkW0GQR1XS
LB1047-RCC	MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTJwN{S4PFgh\|ryP	MlnZV2FPT0WU
SN12C	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTJwOUG5OlQh\|ryP	M4KyOXNCVkeHUh?=
786-0	MoqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTNwME[0NFgh\|ryP	NUH4UIRwW0GQR1XS
HT-29	NUnaOoJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTEXodWUUN3ME2zMlA4OzB7IN88US=>	MYjTRW5ITVJ?
RPMI-7951	NEjERnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfJco9KSzVyPUOuNFc2QSEQvF2=	MWjTRW5ITVJ?
NBsusSR	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFz2U\|dKSzVyPUOuNVgzPTRizszN	NUTYTFU5W0GQR1XS
NKM-1	NGH3[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TLPWlEPTB;Mz6xPFc1PCEQvF2=	NFTxUldUSU6JRWK=
Capan-2	MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rSTWlEPTB;Mz60Olg4PSEQvF2=	NYTtcFdCW0GQR1XS
MKN1	MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4D2XWlEPTB;Mz60O\|ExQCEQvF2=	M{i1VnNCVkeHUh?=
OAW-42	MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\t[WlEPTB;Mz61NFAzPiEQvF2=	M4fq[XNCVkeHUh?=
SKG-IIIa	MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTxTWM2OD1\|LkWyNlM4KM7:TR?=	Mm\MV2FPT0WU
no-11	NVvWeFZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELveoJKSzVyPUOuOVM2PjRizszN	MVXTRW5ITVJ?
NY	NVfLOVY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\STWM2OD1\|LkWzOlU2KM7:TR?=	MmK4V2FPT0WU
HEC-1	NUnMcmpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3STWM2OD1\|LkW4PVUh\|ryP	M33KTXNCVkeHUh?=
NCI-H441	NXfDZZRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlT1TWM2OD1\|LkW5PFQyKM7:TR?=	MX;TRW5ITVJ?
NCI-H2009	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETqbHFKSzVyPUOuOlEzOTZizszN	NH\PXGFUSU6JRWK=
T47D	MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjOTWM2OD1\|Lk[yNlE4KM7:TR?=	NUHL[FBtW0GQR1XS
SNU-449	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLtNZVDUUN3ME2zMlY2QDJ4IN88US=>	MYLTRW5ITVJ?
NCI-SNU-1	M13Wd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7ETVhjUUN3ME2zMlY6PzN3IN88US=>	M1TaSnNCVkeHUh?=
BT-20	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\vUmlEPTB;Mz62PVc6PSEQvF2=	MoLuV2FPT0WU
LS-123	NV6wdZFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknaTWM2OD1\|Lke0Nlg1KM7:TR?=	M4i5O3NCVkeHUh?=
8305C	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlS1TWM2OD1\|Lke1PVEyKM7:TR?=	MUTTRW5ITVJ?
OCUB-M	NGjac\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTNwN{[xPFch\|ryP	M4XuNXNCVkeHUh?=
KOSC-2	NHK2OXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjNO4t6UUN3ME2zMlg{PDVzIN88US=>	M3j2W3NCVkeHUh?=
NCI-H1693	NGXUO49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWW4UodbUUN3ME2zMlg1OThzIN88US=>	Mn7GV2FPT0WU
TE-9	NFTsXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWX4W\|BRUUN3ME2zMlg1Ozh{IN88US=>	M1iy[nNCVkeHUh?=
MV-4-11	M3TjeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHkTWM2OD1\|Lki3PVk1KM7:TR?=	MVTTRW5ITVJ?
GAMG	NHSxVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTNwOUGzNVQh\|ryP	M1PWTXNCVkeHUh?=
KNS-62	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTseXp[UUN3ME2zMlk1PzNzIN88US=>	MnixV2FPT0WU
MC116	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHT4VYlKSzVyPUOuPVU1QDlizszN	Mk\KV2FPT0WU
647-V	NHm4XJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTNwOUi0OVIh\|ryP	MorUV2FPT0WU
U-87-MG	NUCwPYkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXS2U3BNUUN3ME20MlExPDhzIN88US=>	NGDtN2xUSU6JRWK=
RPMI-8226	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTRwMUG2N\|Eh\|ryP	MV3TRW5ITVJ?
SW1417	MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnWSZRKSzVyPUSuNVIyPDdizszN	MV3TRW5ITVJ?
LAMA-84	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jQWWlEPTB;ND6xO\|AzKM7:TR?=	MorvV2FPT0WU
LS-513	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\lNndKSzVyPUSuN\|EzOTdizszN	NVHkUHJKW0GQR1XS
KLE	NEjEWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PEUWlEPTB;ND60NFgyQSEQvF2=	NVjrVnJsW0GQR1XS
HCT-116	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;QbFNKSzVyPUSuOFExODdizszN	NFfLO4RUSU6JRWK=
EPLC-272H	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTzW2NKSzVyPUSuOFE2OzNizszN	MknsV2FPT0WU
KS-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYflemRLUUN3ME20MlUxQDh7IN88US=>	MkizV2FPT0WU
HT-1197	M4TaeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvpWG5KSzVyPUSuOVI3PjlizszN	NIPEcY1USU6JRWK=
LCLC-97TM1	M4\uc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\M[2lEPTB;ND61N\|Y5PiEQvF2=	NVnVSG11W0GQR1XS
ES5	MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13zd2lEPTB;ND64N\|czOyEQvF2=	NHPj[JVUSU6JRWK=
CTB-1	NY\5RmRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXmwWnFsUUN3ME20Mlg1QDhizszN	MYDTRW5ITVJ?
HL-60	NUDhN4o{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFGzRnVKSzVyPUSuPFY3OTFizszN	NVLDTXRqW0GQR1XS
VM-CUB-1	NH\kV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLKbYNvUUN3ME20Mlg3QDF7IN88US=>	NYPDPHhoW0GQR1XS
MEG-01	M1S4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{njZmlEPTB;ND65PVQxOyEQvF2=	Ml;VV2FPT0WU
KYSE-520	M4[3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTVwMkC4N\|kh\|ryP	NUPsTWFNW0GQR1XS
HuO-3N1	M1noOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\tTmlEPTB;NT6yOFA1OyEQvF2=	NF7HSZFUSU6JRWK=
SW620	M2DKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zy[WlEPTB;NT6yOFk3PCEQvF2=	NH[zNIZUSU6JRWK=
U031	NGHyV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTVwMkW0NlQh\|ryP	NVTheWQ2W0GQR1XS
TE-5	M1HzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;SZVNKSzVyPUWuOFA5PSEQvF2=	NFi5d3hUSU6JRWK=
NCI-H747	NXr5WlczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInHOHZKSzVyPUWuOFI1PzJizszN	NIPuXJdUSU6JRWK=
MG-63	NV32WplTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\aVWlEPTB;NT60PFc3OiEQvF2=	M37zbHNCVkeHUh?=
HC-1	M17lNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFWySpdKSzVyPUWuOVE5OzlizszN	M3\CPHNCVkeHUh?=
HCC2998	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\DN2lEPTB;NT61NlYyPSEQvF2=	MYLTRW5ITVJ?
NTERA-S-cl-D1	NWfYXFQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3S5U2lEPTB;NT61OFU{PyEQvF2=	M2XJTnNCVkeHUh?=
KINGS-1	NHHkWnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4G2fWlEPTB;NT62NFk1PCEQvF2=	MnPRV2FPT0WU
D-423MG	NW\tZXNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjJXGxKSzVyPUWuOlE4ODVizszN	NXHRWoQ1W0GQR1XS
SW962	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLJTWM2OD13Lk[yNFMzKM7:TR?=	Mli3V2FPT0WU
LOXIMVI	MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XIbmlEPTB;NT62N\|g4OyEQvF2=	MnPGV2FPT0WU
LS-411N	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PWPGlEPTB;NT63PVQ1OSEQvF2=	M3;4eXNCVkeHUh?=
NCI-H2291	Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17Xb2lEPTB;NT65PFk1OyEQvF2=	NIfjNZBUSU6JRWK=
A549	M4rXe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTZTWM2OD14LkGyOVU{KM7:TR?=	M{XFZXNCVkeHUh?=
LS-1034	M3Hr[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;xVlJKSzVyPU[uNlA4ODZizszN	NFXVUWNUSU6JRWK=
NB14	Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;UNGlEPTB;Nj60N\|g{PiEQvF2=	MXTTRW5ITVJ?
NCI-H1299	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LWemlEPTB;Nj62N\|E4OSEQvF2=	NXrWSJVzW0GQR1XS
BT-549	NYTQSmNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4T4OmlEPTB;Nj62Olg5QSEQvF2=	M1rCOnNCVkeHUh?=
J-RT3-T3-5	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nBWWlEPTB;Nj64Olkh\|ryP	MXXTRW5ITVJ?
SW756	Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnGzTWM2OD14LkmxNVc3KM7:TR?=	MnPBV2FPT0WU
DJM-1	M3\BTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTZwOUKwNVIh\|ryP	NVPjclRoW0GQR1XS
GP5d	NFHkcXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13sWWlEPTB;Nj65O\|M6PCEQvF2=	NWfvSFR5W0GQR1XS
MOLT-4	MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;WfGlEPTB;Nz6wNlE{PSEQvF2=	MVTTRW5ITVJ?
NCI-H28	NWnR[YNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTdwMU[0NFUh\|ryP	NXvaUoZiW0GQR1XS
MN-60	M2XEUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPGe4ZNUUN3ME23MlI5ODh7IN88US=>	MWXTRW5ITVJ?
RMG-I	MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zZO2lEPTB;Nz6zPVI6PiEQvF2=	MV3TRW5ITVJ?
COLO-800	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3n4T2lEPTB;Nz60NVQ1PiEQvF2=	M3fUUXNCVkeHUh?=
DB	NFfVdYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUmzS2tNUUN3ME23MlYyODB3IN88US=>	NFfXeo9USU6JRWK=
Ca-Ski	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4TMO2lEPTB;Nz62OFI2QSEQvF2=	MVrTRW5ITVJ?
HEL	NIDDTZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3WdnBKSzVyPUeuO\|EzODNizszN	NUDxSGg4W0GQR1XS
NH-12	Mon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnvd4FKSzVyPUeuO\|I5ODhizszN	M3XnSHNCVkeHUh?=
LB373-MEL-D	NHTsRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\OTWM2OD15Lke2O\|cyKM7:TR?=	MW\TRW5ITVJ?
SW900	NFz4RoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33hfGlEPTB;Nz64NlEzOSEQvF2=	NELocmpUSU6JRWK=
JVM-3	MmrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTdwOEm1PVkh\|ryP	NWDuem5DW0GQR1XS
OAW-28	Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTdwOUS1O\|gh\|ryP	M2nRenNCVkeHUh?=
KURAMOCHI	NV\CPXlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjNTWM2OD15Lkm0PFEyKM7:TR?=	NYXBTFJwW0GQR1XS
BE-13	M{nk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrNTWM2OD15Lkm4NVEzKM7:TR?=	NGP5c3VUSU6JRWK=
VMRC-RCZ	M17SUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4C5bGlEPTB;OD6wNVY6PyEQvF2=	MUjTRW5ITVJ?
NCI-H727	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nUW2lEPTB;OD6xNFQzKM7:TR?=	NVToWpJDW0GQR1XS
SW1710	M2PnZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTJTWM2OD16LkG4OVE2KM7:TR?=	NEjOWVhUSU6JRWK=
D-502MG	MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLodmRKSzVyPUiuNlkzQDJizszN	MWrTRW5ITVJ?
NCI-H1993	NVXxeW5OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnsV2dKSzVyPUiuN\|M3OzFizszN	NVfBbGZ3W0GQR1XS
SCC-4	NVXsSXFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nH[WlEPTB;OD60OFA2QSEQvF2=	NH7SbYdUSU6JRWK=
HAL-01	NGPad5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRThwNUG5NUDPxE1?	MV\TRW5ITVJ?
GT3TKB	NWexdIh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2Dld2lEPTB;OD62O\|k3PCEQvF2=	M{Dm[3NCVkeHUh?=
SK-OV-3	NGLBdFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPDeJFKSzVyPUiuO\|E{OjlizszN	NHnXbmNUSU6JRWK=
COLO-829	M2HkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPETWM2OD16LkiwPVc3KM7:TR?=	MXXTRW5ITVJ?
OCI-AML2	M4rWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3mfnZKSzVyPUiuPVU1QDFizszN	M13VWHNCVkeHUh?=
OS-RC-2	NE[0UGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHqTWM2OD17LkCyNVkh\|ryP	NImzellUSU6JRWK=
BFTC-909	NWnrc4k2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2Pn[2lEPTB;OT6wOlc6QSEQvF2=	M17nVHNCVkeHUh?=
EW-11	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7sUWVIUUN3ME25MlE4PjV\|IN88US=>	MXXTRW5ITVJ?
HCE-4	NX3HcZdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jIbWlEPTB;OT6yNVU2QCEQvF2=	M3;XN3NCVkeHUh?=
BALL-1	M320fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LWXmlEPTB;OT6yNVkxPyEQvF2=	M3\ZWHNCVkeHUh?=
SF539	M3S1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4D3e2lEPTB;OT6yN\|U3OiEQvF2=	MlHoV2FPT0WU
CAMA-1	Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3j1ZWlEPTB;OT6yPFEzQCEQvF2=	NYrxcFd2W0GQR1XS
C32	M1nO[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfhVmtKSzVyPUmuN\|MxPjRizszN	MWnTRW5ITVJ?
NCI-H1703	MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPDOmZKSzVyPUmuN\|Q{PzVizszN	NXHtZlNCW0GQR1XS
NCI-H1650	NF7CNHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7rdFBxUUN3ME25MlYxQTR4IN88US=>	MlLJV2FPT0WU
NCI-H1563	MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFT0SWtKSzVyPUmuO\|YxOzFizszN	NEDNNmNUSU6JRWK=
CAL-85-1	M1W2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrZdXJKSzVyPUmuPFc{QDNizszN	NXO0NYdDW0GQR1XS
UM-UC-3	MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4W2XWlEPTB;OT65OVA{KM7:TR?=	MULTRW5ITVJ?
BxPC-3	M3HkdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTFyLkC5O\|Ih\|ryP	M2XQbXNCVkeHUh?=
MHH-PREB-1	NXXPb29yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTFyLkG5PVkh\|ryP	NGPrNlZUSU6JRWK=
DEL	NH3S[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXWyeodHUUN3ME2xNE4{QTR4IN88US=>	MoDlV2FPT0WU
HuCCT1	MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTFyLk[wN\|Mh\|ryP	M3XoW3NCVkeHUh?=
OVCAR-4	M4\YZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX25ZodmUUN3ME2xNE45QDN3IN88US=>	MXTTRW5ITVJ?
CAL-72	NXSxclZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETQdGxKSzVyPUGwMlk{QTFizszN	NYXDZ5FKW0GQR1XS
HCC1954	M13ObGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TJO2lEPTB;MUGuNFc2PCEQvF2=	MlnQV2FPT0WU
EFO-21	MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LLUmlEPTB;MUGuNVA1PSEQvF2=	NVzDWVg4W0GQR1XS
FTC-133	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTFzLkG0NFch\|ryP	NGfVPIRUSU6JRWK=
SK-MEL-24	M3XS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Hj[GlEPTB;MUGuNlM3PiEQvF2=	NIH3flNUSU6JRWK=
UACC-62	MnvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLISmhTUUN3ME2xNU4zOzZ6IN88US=>	MmW2V2FPT0WU
NCI-H650	NVnMZYM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;0XmtsUUN3ME2xNU4zPDF6IN88US=>	MmXEV2FPT0WU
ALL-PO	NFXUeY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTFzLkK1NVIh\|ryP	NF3zbo5USU6JRWK=
T84	NXLsS\|JMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTFzLkO5NFch\|ryP	NFnIOnNUSU6JRWK=
IST-MEL1	NV;lS3A6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXiVFZiUUN3ME2xNU41PTV7IN88US=>	NXPvbGhlW0GQR1XS
SW626	M4jw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3S4bmlEPTB;MUGuOVc2PSEQvF2=	MmfqV2FPT0WU
RPMI-2650	NWDke3hCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonkTWM2OD1zMT61PFg2KM7:TR?=	M4f2SHNCVkeHUh?=
MC-IXC	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUT5PYE3UUN3ME2xNU43PzJ6IN88US=>	NHS4[3FUSU6JRWK=
HOP-62	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfiSXB1UUN3ME2xNU43PzZ2IN88US=>	NFHoWIxUSU6JRWK=
NOS-1	MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXOWXZKSzVyPUGxMlcyODlizszN	NXHsc3JiW0GQR1XS
SW1573	NXXa[Ws6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjEOZlKSzVyPUGxMlczQTVizszN	MnzVV2FPT0WU
WM-115	NITmWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTFzLke1PFgh\|ryP	Mm\LV2FPT0WU
HuO9	MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnzZpdKSzVyPUGxMlg4PzRizszN	NVjaXZFIW0GQR1XS
YAPC	M4P5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXwN4ZKSzVyPUGxMlkzPTlizszN	NWLzXYZuW0GQR1XS
MDA-MB-453	NHHZZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTFzLkm1NVUh\|ryP	MYfTRW5ITVJ?
NCI-H596	M4nW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3[1NWlEPTB;MUKuNFM3QSEQvF2=	M2qzTHNCVkeHUh?=
A172	MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmW1TWM2OD1zMj6wO\|k5KM7:TR?=	NUG3WHhlW0GQR1XS
RS4-11	NUXOcG05T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfENHNKSzVyPUGyMlE4OjVizszN	NYTlU2VUW0GQR1XS
HCC1937	M17XWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TPNGlEPTB;MUKuO\|U3PCEQvF2=	M1;JR3NCVkeHUh?=
SW837	NWHKPHVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2Toc2lEPTB;MUKuPVAzQCEQvF2=	M4LtenNCVkeHUh?=
NMC-G1	NV7aS3Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2H6d2lEPTB;MUKuPVI{PCEQvF2=	Mo[xV2FPT0WU
PFSK-1	M3\PZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTF\|LkC2JO69VQ>?	MoS4V2FPT0WU
DBTRG-05MG	NV7adFFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPzXGdKSzVyPUGzMlA3OzJizszN	NFHmZ3VUSU6JRWK=
SK-UT-1	MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXW[40zUUN3ME2xN{4yODh\|IN88US=>	NHexdolUSU6JRWK=
OVCAR-5	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;6RWlEPTB;MUOuNVU6OyEQvF2=	M3mybnNCVkeHUh?=
8505C	M3\mc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHhdmpuUUN3ME2xN{4zODZ5IN88US=>	NYHkeYlnW0GQR1XS
SK-MEL-1	MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTF\|LkexN\|Uh\|ryP	NVjRflZYW0GQR1XS
LK-2	NXPLVWdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTF\|Lke2N\|kh\|ryP	MofUV2FPT0WU
OE33	NWX1VJVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmj2TWM2OD1zMz63PFYh\|ryP	MULTRW5ITVJ?
Ramos-2G6-4C10	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vaXmlEPTB;MUSuNFIxOiEQvF2=	M1LnV3NCVkeHUh?=
EW-13	M4\hcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3m2dmlEPTB;MUSuNFM2OiEQvF2=	NVnx[5ZOW0GQR1XS
NCI-H1793	NI\XV2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPoU3RUUUN3ME2xOE4zODh5IN88US=>	MVLTRW5ITVJ?
BHT-101	MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzzXYRSUUN3ME2xOE4zPDFizszN	MWjTRW5ITVJ?
RKO	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3K3OGlEPTB;MUSuOVA4PSEQvF2=	NGLWbYlUSU6JRWK=
NEC8	MlnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkn3TWM2OD1zND61OFczKM7:TR?=	NWHQdlhZW0GQR1XS
PANC-10-05	MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTF2Lk[yOFch\|ryP	MU\TRW5ITVJ?
NCI-H2030	MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzwTWM2OD1zND62OFQ5KM7:TR?=	NESxWZpUSU6JRWK=
C2BBe1	MkjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fIUmlEPTB;MUSuO\|Y1KM7:TR?=	NFTaZnZUSU6JRWK=
EM-2	M4ryU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XYN2lEPTB;MUSuPFU4PiEQvF2=	NYrKW3I2W0GQR1XS
HCC1395	NEmyNmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fLPGlEPTB;MUSuPVM{QCEQvF2=	MnvwV2FPT0WU
A2058	MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGm3W4FKSzVyPUG1MlA1ODlizszN	NXjZZYtiW0GQR1XS
SW1463	M4LuNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXSy[WNWUUN3ME2xOU4xPDh3IN88US=>	M3PRZXNCVkeHUh?=
J82	MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHZSlVKSzVyPUG1MlA2PyEQvF2=	M2DHVXNCVkeHUh?=
CAL-120	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTF3LkG0OFch\|ryP	NIj4bZVUSU6JRWK=
COLO-824	M{DiO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmW3TWM2OD1zNT6xOVc6KM7:TR?=	MYnTRW5ITVJ?
LNCaP-Clone-FGC	M3yyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTF3LkSyOFgh\|ryP	MVrTRW5ITVJ?
CP66-MEL	NHnXeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3POcmlEPTB;MUWuOFY5QCEQvF2=	M3rFNnNCVkeHUh?=
OC-314	NXHoVHVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3Ln[2lEPTB;MUWuOFcyPCEQvF2=	NIHPXoNUSU6JRWK=
OVCAR-8	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV:0PGpYUUN3ME2xOU45QDZzIN88US=>	MXTTRW5ITVJ?
MFE-280	M1vaUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVq4V41VUUN3ME2xOk4xPDh6IN88US=>	NIfUdZZUSU6JRWK=
MHH-NB-11	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTOTWM2OD1zNj6wPFM6KM7:TR?=	MV7TRW5ITVJ?
SW1990	M4fTXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPrSFczUUN3ME2xOk4yPzV3IN88US=>	MUPTRW5ITVJ?
U-266	MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTF4LkKyPVkh\|ryP	M4XrWXNCVkeHUh?=
MFM-223	NV3xS\|BHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfrTWM2OD1zNj6zPVY2KM7:TR?=	M4LOTXNCVkeHUh?=
L-363	MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPVPXZrUUN3ME2xOk41PTd5IN88US=>	M{O1bHNCVkeHUh?=
MCF7	Ml\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vQSmlEPTB;MU[uOFczOyEQvF2=	M33seHNCVkeHUh?=
SK-MEL-3	NWL4emNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDxTWM2OD1zNj60O\|g4KM7:TR?=	MX3TRW5ITVJ?
HH	M4[yOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTyd\|VKSzVyPUG2MlUyPjJizszN	NF;nfmZUSU6JRWK=
no-10	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTF4Lk[zOFMh\|ryP	NYLVfYNvW0GQR1XS
HuP-T3	NVX3T2hbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\6ZlR5UUN3ME2xOk43PTd4IN88US=>	MkGzV2FPT0WU
QIMR-WIL	MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrFU5ZbUUN3ME2xOk44OTB3IN88US=>	NWfnPG9XW0GQR1XS
NCI-H1092	M4T1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXLdHlKSzVyPUG2Mlg{OTZizszN	NX7Oc3o1W0GQR1XS
MZ2-MEL	NETBOHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nqNWlEPTB;MU[uPFQxOyEQvF2=	NE\BdYpUSU6JRWK=
ES3	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXNTWM2OD1zNj65NVM1KM7:TR?=	M3zVUnNCVkeHUh?=
COLO-684	Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTF4Lkm0O\|ch\|ryP	MUjTRW5ITVJ?
NCI-H661	NFvqb45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjYeGs4UUN3ME2xOk46Pjl2IN88US=>	MWjTRW5ITVJ?
CP50-MEL-B	NYHBdHhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIi5ZlZKSzVyPUG3MlA{PDNizszN	M2\ERXNCVkeHUh?=
NCI-H2405	MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLDWoJTUUN3ME2xO{4yQTd2IN88US=>	NEDFRVlUSU6JRWK=
U-2-OS	Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTF5LkWzNFch\|ryP	MlvkV2FPT0WU
RERF-LC-MS	NWLSenl3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3CcHdKSzVyPUG3MlU2ODhizszN	NIrvSIlUSU6JRWK=
NCI-H2342	NFLRTFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\VTWM2OD1zNz61OVch\|ryP	M3iwOnNCVkeHUh?=
ES8	M{LPUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{W0[GlEPTB;MUeuOlA5PyEQvF2=	MWjTRW5ITVJ?
MOLT-16	M{jhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonJTWM2OD1zNz64PVM1KM7:TR?=	MkHnV2FPT0WU
RH-18	NFf5ZYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDpTWM2OD1zOD6wNFM2KM7:TR?=	M2LYXXNCVkeHUh?=
D-283MED	NVruNZdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjHTnl2UUN3ME2xPE4xODh6IN88US=>	NIjxXmNUSU6JRWK=
RCC10RGB	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrDcodKSzVyPUG4MlA2PTlizszN	Ml3UV2FPT0WU
NCI-H1437	NHiwXppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlL4TWM2OD1zOD6xOlQyKM7:TR?=	NY\2cmYxW0GQR1XS
SW982	NHL6UpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTF6LkK2O\|Eh\|ryP	NIL6TVNUSU6JRWK=
IST-MES1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\jPJNnUUN3ME2xPE41PDJ6IN88US=>	MoXxV2FPT0WU
A704	NIDoPGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTCTWM2OD1zOD60O\|U{KM7:TR?=	MoHSV2FPT0WU
ESS-1	M1PjRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTF6LkWyNFUh\|ryP	NIHhW25USU6JRWK=
SCH	M1PMbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFq4OmdKSzVyPUG4MlY1PTZizszN	Mn;yV2FPT0WU
COLO-320-HSR	M1nCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXhVldKUUN3ME2xPE44PDZizszN	M{\iTXNCVkeHUh?=
Mo-T	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmG4TWM2OD1zOD64NlA1KM7:TR?=	MYHTRW5ITVJ?
Saos-2	MlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkmwTWM2OD1zOT6xNVYzKM7:TR?=	NXPvWJVPW0GQR1XS
SW684	NXPwZnVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3ezPGlEPTB;MUmuNVMzPiEQvF2=	NXe3Z2p[W0GQR1XS
KMOE-2	M13pNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\NR4xDUUN3ME2xPU4zOjR{IN88US=>	NUX2So15W0GQR1XS
MMAC-SF	MlrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1z3b2lEPTB;MUmuNlYxPyEQvF2=	NXfLNoE2W0GQR1XS
JAR	MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTF7LkK5PUDPxE1?	MkjSV2FPT0WU
SK-MEL-28	NIjqTIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPhUodKSzVyPUG5MlM{PjNizszN	MXvTRW5ITVJ?
KNS-81-FD	Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTF7LkW0Olgh\|ryP	NIC3eGVUSU6JRWK=
ES7	NH[2[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfSTWM2OD1zOT62NlkzKM7:TR?=	MnTHV2FPT0WU
AsPC-1	NWDV[\|FzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTF7Lk[0O\|Eh\|ryP	M1O3bnNCVkeHUh?=
NCI-H1155	M{eyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTF7LkeyN\|gh\|ryP	NYXv[XdnW0GQR1XS
KYSE-510	NVn2WG5ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDIOndKSzVyPUG5Mlg4PDhizszN	NHjTZXNUSU6JRWK=
ES1	MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7kTWM2OD1zOT65NlE{KM7:TR?=	MmG1V2FPT0WU
PC-3	NGPVWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjYTIdKSzVyPUG5Mlk3ODRizszN	M4HU[HNCVkeHUh?=
GCT	M1nYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH:xSZBKSzVyPUKwMlMxOjZizszN	MWnTRW5ITVJ?
KARPAS-299	NWLNWYtCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\ITWM2OD1{MD6zOFIzKM7:TR?=	MUHTRW5ITVJ?
DOHH-2	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDXTWM2OD1{MD61OFY{KM7:TR?=	MnjNV2FPT0WU
COLO-741	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rmWmlEPTB;MkCuOlYh\|ryP	NHHEV\|VUSU6JRWK=
NCI-H1395	M1uzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTJyLk[2PVch\|ryP	NYCxepE4W0GQR1XS
HCC1187	NU\sdFJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7LXmFKSzVyPUKwMlY4OzRizszN	NXPLZ5lLW0GQR1XS
Becker	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPob2JKSzVyPUKwMlczODFizszN	M2jVeXNCVkeHUh?=
LU-134-A	NIXSbHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTJzLkGwNlYh\|ryP	Mk\nV2FPT0WU
MKN45	NV;wVHVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjmXJdRUUN3ME2yNU4yPTVzIN88US=>	MVHTRW5ITVJ?
LC-2-ad	M2r5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTJzLkK3Nlkh\|ryP	MYXTRW5ITVJ?
EW-24	M2nBUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFyyZVlKSzVyPUKxMlM6PDVizszN	NGDFSWpUSU6JRWK=
SK-N-AS	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTJzLkiyO\|Yh\|ryP	NWLiVVdoW0GQR1XS
NCI-H2052	M{HtdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;kZ5VKSzVyPUKxMlg6PjNizszN	NV7iVWt3W0GQR1XS
A4-Fuk	M3OzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\QVWlEPTB;MkKuNVQyQSEQvF2=	MWXTRW5ITVJ?
NB10	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HYT2lEPTB;MkKuNlM4OSEQvF2=	NI\3Z4RUSU6JRWK=
CHP-212	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFmxUZRKSzVyPUKyMlMzOjJizszN	Mm\iV2FPT0WU
KM12	NVTpT\|dPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TuUGlEPTB;MkKuN\|U3KM7:TR?=	NYf3bpFLW0GQR1XS
JEG-3	MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nOVmlEPTB;MkKuN\|c5KM7:TR?=	MlPNV2FPT0WU
LN-405	MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTJ{LkW5NVMh\|ryP	MXLTRW5ITVJ?
HCT-15	Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvlW\|NCUUN3ME2yNk44PDRzIN88US=>	MlHPV2FPT0WU
MLMA	M{S3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTJ{Lke0O{DPxE1?	NV;LSlROW0GQR1XS
GI-1	M{Phemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTJ{Lke2OVgh\|ryP	NY\pPZdLW0GQR1XS
RT-112	NV2yUFNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfCTWM2OD1{Mj64OlE3KM7:TR?=	MXnTRW5ITVJ?
MPP-89	NHnFd3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTJ{Lki2OlEh\|ryP	M{K0fnNCVkeHUh?=
A3-KAW	M37KRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjDNpNjUUN3ME2yN{4yODB\|IN88US=>	MUHTRW5ITVJ?
KALS-1	NFXQNmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjqd4pKSzVyPUKzMlE1OTRizszN	NVrVU3dPW0GQR1XS
SF126	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnCeYFKSzVyPUKzMlY6OjRizszN	MYDTRW5ITVJ?
SiHa	NIq2VYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonOTWM2OD1{Mz65N\|I4KM7:TR?=	NULaZotrW0GQR1XS
MDA-MB-415	NFr1UYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDsblBTUUN3ME2yN{46PDl7IN88US=>	M12yPXNCVkeHUh?=
Daoy	NI[0NmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfIWGRKSzVyPUK0MlEzPiEQvF2=	M3TEfnNCVkeHUh?=
COR-L23	Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorvTWM2OD1{ND6xO\|Y4KM7:TR?=	M3vz[nNCVkeHUh?=
KG-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTJ2LkG5Nlgh\|ryP	Mo[wV2FPT0WU
L-428	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTJ2LkW3PVEh\|ryP	NVHSeHoxW0GQR1XS
NCI-H520	NYfRdXRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTJ2Lki4OlEh\|ryP	MVfTRW5ITVJ?
COLO-792	M2j4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\m[lUyUUN3ME2yOU4zPzN{IN88US=>	MX3TRW5ITVJ?
NB12	M3f5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTJ3LkK5OFch\|ryP	NWSwfHhRW0GQR1XS
GAK	MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\3UZFPUUN3ME2yOU4zQTZ\|IN88US=>	NHv6ZXNUSU6JRWK=
SW780	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HoUWlEPTB;MkWuN\|I3PCEQvF2=	NI\KSI5USU6JRWK=
GB-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUf6cJp6UUN3ME2yOU41ODZ7IN88US=>	MXnTRW5ITVJ?
P12-ICHIKAWA	MoPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnwTWM2OD1{NT60O\|g2KM7:TR?=	NHPreXVUSU6JRWK=
NCI-H1651	NGLkPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHLUplKSzVyPUK1MlU6PyEQvF2=	NGDvdXBUSU6JRWK=
KE-37	M2nBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTJ3LkezNVUh\|ryP	M4DMRXNCVkeHUh?=
CCRF-CEM	NYD5[WFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHydI5KSzVyPUK1Mlk3PyEQvF2=	NXLzZY9jW0GQR1XS
SF295	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\0dWlEPTB;Mk[uNFQzPSEQvF2=	NX;qdXY3W0GQR1XS
G-361	NGTL[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTJ4LkGwNlch\|ryP	MnTrV2FPT0WU
HOP-92	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfZNGZHUUN3ME2yOk4yOjJ4IN88US=>	NGnSXYFUSU6JRWK=
UMC-11	MnjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;PO5FUUUN3ME2yOk41PTF2IN88US=>	MUPTRW5ITVJ?
IST-SL1	NYLRRWdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTRTWM2OD1{Nj62OVkyKM7:TR?=	NHeyZnlUSU6JRWK=
TE-11	NUTrSFJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jMfmlEPTB;Mk[uO\|c2OiEQvF2=	M3judnNCVkeHUh?=
NCI-H1304	NF\KSHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTJ4LkmxNFgh\|ryP	M4XmNHNCVkeHUh?=
SJSA-1	NGLDUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{[3VWlEPTB;MkeuNFE4PiEQvF2=	M125U3NCVkeHUh?=
BCPAP	MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTJ5LkGzO{DPxE1?	MYfTRW5ITVJ?
HTC-C3	M33kVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTJ5LkK1OlEh\|ryP	M135UXNCVkeHUh?=
EW-16	M2TLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDvdJFKSzVyPUK3MlI6PDdizszN	M3jFdnNCVkeHUh?=
HT-144	NVe3cW5GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYW5cGIyUUN3ME2yO{41ODN{IN88US=>	MnLKV2FPT0WU
MHH-ES-1	M3PoXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTJ5LkS0OFch\|ryP	MmOwV2FPT0WU
T98G	NEXIWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XKbmlEPTB;MkeuOVg1PiEQvF2=	NGPUZWhUSU6JRWK=
RPMI-8866	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTJ5Lke1OlIh\|ryP	MnryV2FPT0WU
BEN	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTJ5Lki1NVch\|ryP	NF\XbHVUSU6JRWK=
MDA-MB-231	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfCTWM2OD1{OD6yO\|k2KM7:TR?=	NUTJSYx5W0GQR1XS
HuH-7	NX22bm45T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\Dfm9KSzVyPUK4MlQxOjhizszN	MonXV2FPT0WU
SK-N-FI	NFuyXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XqRWlEPTB;MkiuOFM{KM7:TR?=	NFPa[YxUSU6JRWK=
AN3-CA	NFfpWGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPhXJVKSzVyPUK4MlQ{QTVizszN	NVv4Z\|U3W0GQR1XS
EGI-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXGxSVJYUUN3ME2yPE42QTJ6IN88US=>	MUXTRW5ITVJ?
697	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37abWlEPTB;MkiuOlM{OSEQvF2=	M4CyPHNCVkeHUh?=
TCCSUP	NWjFbXVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLqdZlUUUN3ME2yPE43PDF6IN88US=>	MoLsV2FPT0WU
GR-ST	NIXBWWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{K5bGlEPTB;MkiuOlY6PiEQvF2=	NHjUenRUSU6JRWK=
SK-N-DZ	M13TeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XpRWlEPTB;MkiuOlg5PSEQvF2=	NYDQc2dbW0GQR1XS
MIA-PaCa-2	M4XIfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nJWWlEPTB;MkiuO\|k2QSEQvF2=	NHXQN2hUSU6JRWK=
IGR-1	NWLPdph5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIqyb3hKSzVyPUK4Mlg5PzRizszN	NUTae25DW0GQR1XS
BFTC-905	MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHwZ29KSzVyPUK5MlI4ODVizszN	NHrzS2tUSU6JRWK=
NCI-H1581	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTJ7LkOxOFUh\|ryP	NGHxc5pUSU6JRWK=
RD	M{XI[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml:zTWM2OD1{OT61NlM{KM7:TR?=	MlqzV2FPT0WU
SF268	MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTJ7LkW5N\|Eh\|ryP	MoPRV2FPT0WU
SHP-77	NGnUbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3pSY1pUUN3ME2yPU43OTh{IN88US=>	M4jRWHNCVkeHUh?=
D-566MG	NX7RdFZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTJ7LkmzPVMh\|ryP	MUPTRW5ITVJ?
TGBC1TKB	NXPxOVhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\hOZVPUUN3ME2zNE4yOjN6IN88US=>	M3njW3NCVkeHUh?=
MEL-HO	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\jTWM2OD1\|MD6xOFI{KM7:TR?=	NYHlUVN4W0GQR1XS
SJRH30	NXH1VlZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml73TWM2OD1\|MD6yNVA5KM7:TR?=	M1HiTHNCVkeHUh?=
D-336MG	MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTNyLkK4PVIh\|ryP	NYXrXXV5W0GQR1XS
C3A	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjLTWM2OD1\|MD6yPVI4KM7:TR?=	NHrWPI1USU6JRWK=
Calu-6	MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTNyLkK5OlMh\|ryP	MUTTRW5ITVJ?
MZ1-PC	NFzJ[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLTfW5uUUN3ME2zNE4{QTNizszN	NFS0W\|JUSU6JRWK=
KYSE-70	NFS3dVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTNyLkWxNVQh\|ryP	NVH1PIFNW0GQR1XS
CAPAN-1	M3vF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTNyLkWxPFEh\|ryP	NYi4WpVjW0GQR1XS
DK-MG	NEG0RWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTNyLkW0OVYh\|ryP	NYSwSGxPW0GQR1XS
SK-HEP-1	M4Hnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTNyLk[zNlYh\|ryP	Ml;HV2FPT0WU
MS-1	M{LKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTJTWM2OD1\|MD64PFg6KM7:TR?=	M3TuRnNCVkeHUh?=
GI-ME-N	NYLyZnBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mkm4TWM2OD1\|MT6wOVcyKM7:TR?=	Ml3TV2FPT0WU
NCI-H510A	M4Oye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTNzLkSwNFYh\|ryP	MlPkV2FPT0WU
NB17	NXnpcHRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7h[5lKSzVyPUOxMlUyQDVizszN	NV;He\|VZW0GQR1XS
639-V	M3mzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYP2NlFLUUN3ME2zNU42OjR\|IN88US=>	MnrmV2FPT0WU
CAL-51	MkjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3UTWM2OD1\|MT61OlY4KM7:TR?=	Mke5V2FPT0WU
HGC-27	M1TFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zsTmlEPTB;M{GuOVg4OyEQvF2=	NIf2eIxUSU6JRWK=
GOTO	Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHYUVJnUUN3ME2zNU45PTB4IN88US=>	NGXPR4hUSU6JRWK=
ChaGo-K-1	MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3Hd5VxUUN3ME2zNk4xODdizszN	MYrTRW5ITVJ?
RO82-W-1	NWDCcGZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTN{LkG2NFQh\|ryP	M4juR3NCVkeHUh?=
SH-4	NIXvOFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\OUFlLUUN3ME2zNk4yQDV6IN88US=>	NYezb4JwW0GQR1XS
A204	NGqyOXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjpNVBKSzVyPUOyMlUxPjlizszN	NXzwNYxMW0GQR1XS
DMS-273	MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHjTWM2OD1\|Mj61N\|IzKM7:TR?=	MVjTRW5ITVJ?
KGN	M3i2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTN{Lk[zN{DPxE1?	NYK3PVZ6W0GQR1XS
SK-MEL-2	NFfneGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfoZ5RKSzVyPUOyMlY2OjdizszN	M1LiXnNCVkeHUh?=
NCI-H2228	NUfYNpY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nZU2lEPTB;M{KuOlYxOiEQvF2=	NXTYcYx5W0GQR1XS
MKN28	NGfaWG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;kT2lEPTB;M{KuO\|g{QCEQvF2=	MX7TRW5ITVJ?
H-EMC-SS	MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jte2lEPTB;M{KuPVY4QCEQvF2=	Mn2yV2FPT0WU
ATN-1	NIXvPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXuTWM2OD1\|Mz6xOFE3KM7:TR?=	MYLTRW5ITVJ?
D-263MG	M3LY[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TCTGlEPTB;M{OuPFM4QCEQvF2=	M2HJUnNCVkeHUh?=
LU-135	M3nyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rpVmlEPTB;M{OuPFgzQSEQvF2=	MojmV2FPT0WU
C8166	NIjm[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnGxTWM2OD1\|Mz64PFU1KM7:TR?=	NXXv[3lGW0GQR1XS
T-24	NYrDfnd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYr0[ZREUUN3ME2zOE4xOjB3IN88US=>	M1f3cnNCVkeHUh?=
Mewo	M3izZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnHVItKSzVyPUO0MlE{PDlizszN	M{LzWHNCVkeHUh?=
22RV1	M2faVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUj2NJZHUUN3ME2zOE4yPzV2IN88US=>	NITzfpBUSU6JRWK=
KM-H2	NGWyN3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vW[mlEPTB;M{SuNVc4QSEQvF2=	MVHTRW5ITVJ?
NCI-H2122	MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml71TWM2OD1\|ND6zOFcyKM7:TR?=	NEHGVItUSU6JRWK=
ABC-1	MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTN2LkO2PVMh\|ryP	NHHFdZpUSU6JRWK=
NCI-H1355	NI\qV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTLTWM2OD1\|ND6zPFg6KM7:TR?=	M37iWnNCVkeHUh?=
NOMO-1	MmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnS1TWM2OD1\|ND61O\|A{KM7:TR?=	NWXofGhwW0GQR1XS
MZ7-mel	NULzeGo1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkCwTWM2OD1\|ND62OFg4KM7:TR?=	NYCzcWtuW0GQR1XS
NCI-H810	M{CzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnWTWM2OD1\|ND63Nlc5KM7:TR?=	MULTRW5ITVJ?
D-392MG	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jrPGlEPTB;M{WuNFU3PSEQvF2=	M3K0bXNCVkeHUh?=
LB771-HNC	NE\Xd5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\UR4dUUUN3ME2zOU4yPjV6IN88US=>	NGXibW1USU6JRWK=
COLO-679	M1LRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvERWFKSzVyPUO1MlM5QCEQvF2=	MmfXV2FPT0WU
SK-PN-DW	M{ixSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTN3LkSzOlkh\|ryP	NXnrTG5oW0GQR1XS
VA-ES-BJ	NWe0W5ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTN3LkS2OFkh\|ryP	NYS1cWF1W0GQR1XS
KNS-42	NWK3UFFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;ETWM2OD1\|NT61PFI3KM7:TR?=	NEDqWIpUSU6JRWK=
RVH-421	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWiwfmUxUUN3ME2zOU44PjR3IN88US=>	NEjyW29USU6JRWK=
P30-OHK	NVvKXZFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTN3Lki3OVIh\|ryP	MXvTRW5ITVJ?
G-402	MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlGyTWM2OD1\|NT65PFY4KM7:TR?=	MVTTRW5ITVJ?
S-117	NXnsPVBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTDTWM2OD1\|Nj6zNFA5KM7:TR?=	MlnNV2FPT0WU
RXF393	NHXscVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTN4LkO3PFUh\|ryP	NXTjWWt1W0GQR1XS
LCLC-103H	M{TaZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13TSGlEPTB;M{[uO\|gxOyEQvF2=	NXy5SJlRW0GQR1XS
U-118-MG	NGDGUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTN4Lki4OFch\|ryP	NV7mR5RRW0GQR1XS
8-MG-BA	NYfDbZVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vtc2lEPTB;M{[uPVQ5OyEQvF2=	NHTzVmNUSU6JRWK=
MFH-ino	NIDuNlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\hcpo5UUN3ME2zO{4{OzdzIN88US=>	MWHTRW5ITVJ?
NCI-H23	MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrXW4tKSzVyPUO3MlQyQTZizszN	M3W1OXNCVkeHUh?=
NCI-H446	M2qzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml[5TWM2OD1\|Nz60PFYzKM7:TR?=	MXXTRW5ITVJ?
LU-99A	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIOzeFhKSzVyPUO3MlU4OzFizszN	MkH6V2FPT0WU
KP-N-YN	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPkb\|dKSzVyPUO3MlYyQTVizszN	MoTxV2FPT0WU
SCC-9	NUWwdlBVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLPXHBTUUN3ME2zO{44QDN6IN88US=>	NFy1Nm9USU6JRWK=
EFM-19	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3NdYhKSzVyPUO3Mlc6PjdizszN	Mlv4V2FPT0WU
A427	MnHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mki4TWM2OD1\|Nz65NVA4KM7:TR?=	MU\TRW5ITVJ?
LB831-BLC	NVvy[IlmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\6XmlEPTB;M{iuOlA{QSEQvF2=	NWfOVINZW0GQR1XS
HOS	M1PQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TtPGlEPTB;M{muOlI4OyEQvF2=	NYfOTFR[W0GQR1XS
LAN-6	MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTRyLkCxNVIh\|ryP	MWnTRW5ITVJ?
U251	MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrmZmZnUUN3ME20NE41ODV2IN88US=>	NVzqXGtMW0GQR1XS
SNU-387	M{jIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\EW5h3UUN3ME20NE41PTV\|IN88US=>	NILiXHFUSU6JRWK=
DMS-79	NED6bndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTRyLkW4PFkh\|ryP	NXGzXmR3W0GQR1XS
SK-LU-1	NYrodVdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mln1TWM2OD12MD62OVY5KM7:TR?=	MmPRV2FPT0WU
HT	MnPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTRyLk[2N\|kh\|ryP	NFLGS21USU6JRWK=
KP-N-YS	M4jKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPpTWM2OD12MD62O\|Y5KM7:TR?=	MmC5V2FPT0WU
DMS-114	MlHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHHTmNKSzVyPUSwMlg{PzRizszN	NULwTIZNW0GQR1XS
HUTU-80	MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXr6WlBQUUN3ME20NU4xPTZ7IN88US=>	NWWyRnlxW0GQR1XS
ONS-76	NXrFOJFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTRzLkS3NFkh\|ryP	MkPXV2FPT0WU
A673	NUjvOXp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLhTWM2OD12MT61NVU4KM7:TR?=	MV3TRW5ITVJ?
HPAF-II	NYK0U2dyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\aVG13UUN3ME20NU43PzB7IN88US=>	NGS0SYpUSU6JRWK=
UACC-257	M4C1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1:3[WlEPTB;NEGuO\|M3QSEQvF2=	MVPTRW5ITVJ?
EW-22	NXnKRoFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfL[FRKSzVyPUSxMlg3QTdizszN	M2DiUHNCVkeHUh?=
NCI-H1755	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTRzLki3NlUh\|ryP	M2DMXHNCVkeHUh?=
KYSE-150	MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHNdmFKSzVyPUSyMlE4QDJizszN	M{\DVnNCVkeHUh?=
CGTH-W-1	NF;JSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfteXhKSzVyPUSyMlQ6PTVizszN	M1XVWnNCVkeHUh?=
NB13	M1\T[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\XTWM2OD12Mj62NlE4KM7:TR?=	NVexWFhZW0GQR1XS
SW872	NUfONINNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LJSWlEPTB;NEKuOlM{OSEQvF2=	NF\V[ItUSU6JRWK=
KP-4	Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDkTWM2OD12Mj64PFMzKM7:TR?=	NVzZbJNHW0GQR1XS
HCC38	NWq5bZR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTDV3RKSzVyPUSyMlk3OThizszN	NXrWWFFsW0GQR1XS
BB49-HNC	MlvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1P2RmlEPTB;NEOuNlM2PiEQvF2=	NF;qbHVUSU6JRWK=
CAL-62	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7GeYJKSzVyPUSzMlQxOjhizszN	M13WW3NCVkeHUh?=
NCI-H2029	MkPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTR\|LkW1PFEh\|ryP	NETvcWtUSU6JRWK=
M14	NILFd5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\IcFRKSzVyPUS0MlE{OzJizszN	M3LJb3NCVkeHUh?=
COLO-680N	NFzL[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTR2LkOzPUDPxE1?	M2\UNXNCVkeHUh?=
Hs-578-T	NWnm[GJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLXTWM2OD12NT6wNlk1KM7:TR?=	MYHTRW5ITVJ?
MSTO-211H	NU\q[\|B4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\L[GlEPTB;NEWuPVQ5OiEQvF2=	MkezV2FPT0WU
EW-1	NVTOSWNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nQV2lEPTB;NEWuPVY5QSEQvF2=	NXS3UGNkW0GQR1XS
SW948	NHO2b2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3H0VGlEPTB;NE[uOFQ3OiEQvF2=	M3G2enNCVkeHUh?=
NCI-H460	Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vYZmlEPTB;NE[uOVI{KM7:TR?=	NXXERoF3W0GQR1XS
CAS-1	NVPKSogyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTR4Lke3NFEh\|ryP	NWnySlJsW0GQR1XS
TGBC11TKB	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M134eGlEPTB;NEeuNVc4PyEQvF2=	NUTXSY5PW0GQR1XS
HD-MY-Z	NYj2XlBlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDlcG1KSzVyPUS4Mlc5PiEQvF2=	MV\TRW5ITVJ?
NCI-H226	NWXTU5R3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvDOZNKSzVyPUS5Mlc4QDVizszN	NUflcFFCW0GQR1XS
PA-1	NIj0W5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfpTWM2OD12OT64N\|M2KM7:TR?=	NV7WeXhXW0GQR1XS
LB2518-MEL	MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfnOoJtUUN3ME20PU45PzJ\|IN88US=>	NIjDdVZUSU6JRWK=
A101D	MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXGSXdKSzVyPUS5Mlk1OjVizszN	MULTRW5ITVJ?
NCI-H2087	M2nKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILxSHhKSzVyPUS5Mlk3QDJizszN	NIPJd4RUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	CIP2A / p-AKT / AKT / PARP; PubMed: 25537503 Oncotarget Time-dependent effects of afatinib on CIP2A, p-AKT and apoptosis-related proteins in the sensitive H358 and resistant H460 cells. Cells were exposed to 10 μM afatinib for up to 48 hours. Immunoblots were scanned and quantitated to determine the ratio of the level of CIP2A to actin. Data are mean ± SD. n = 3 for the different time intervals. p-EGFR / p-IGF1R / p-ERK / p-AKT; PubMed: 26052929 Mol Carcinog Effects of afatinib on EGFR and IGF1R Signaling Pathways. H1975 cells were treated with afatinib with various doses and cell lysates were subjected to Western blot analysis. Afatinib effectively inhibits p-EGFR and p-ERK while p-AKT was partially inhibited. IGF1R phosphorylation was increased upon afatinib treatment in H1975 cells. p-VEGFR2 / VEGFR2 / JAG1 / DLL4 / NICD1 ; PubMed: 28533486 Oncotarget HUVECs were cultured in the presence of Vatalanib (100 nM) or DBZ (10 nM) for 1 h and then treated for 15 min with rhgal-3 (37 nM) and cultured for additional 6 hrs. After this period, the total protein was isolated and the protein levels of galectin-3, NICD1, DLL4, JAG1, VEGFR2 and VEGFR2-p were assessed by Western blot. β-actin was used as a loading control.	25537503 26052929 28533486
Growth inhibition assay	Cell apoptosis; PubMed: 25537503 Oncotarget Dose-dependent effects of afatinib on apoptosis. Data are mean ± SD. n = 3 for each concentration. , p < 0.05, *, p < 0.01, vs. no afatinib. Cell viability; PubMed: 26515464 Oncotarget A. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion and L858R. The proportional cell viability is shown. B. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion+T790M and L858R+T790M. The proportional cell viability is shown. C. MTS assay for Ba/F3 cells harboring wild type EGFR. The proportional cell viability is shown. Erlotinib, afatinib, osimertinib, and rociletinib were used as EGFR-TKIs. Error bars indicate standard deviation.	25537503 26515464
Immunofluorescence	p65; PubMed: 26317651 Oncotarget Effects of different treatments on the nuclear translocation of the NF-κB subunit p65. A2780T cells were treated with 2.5 μM afatinib for 48 hours, or 10 μM PDTC for 2 hours. Subsequently, the NF-κB subunit p65 (red) was localized by immunofluorescence and a confocal microscopy. Nuclei were stained with DAPI (blue). Scale bar = 10 μM. vacuoles; PubMed: 29713246 Cancer Cell Int Autophagy activation upon treatment with Afatinib and Sorafenib was validated using immunofluorescence in order to visualize a creation of autophagosomes; ×60 magnification. DMSO treatment was used as control. Green—autophagy vacuoles; Blue—Hoechst, nuclear staining.	26317651 29713246

In vivo

Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies. ^[1]

Protocol

Kinase Assay: ^[1]	+ Expand In vitro kinase activity assays: The wild type tyrosine kinase domain of the human EGFR as well as that of the EGFR L858R/T790M double mutant are fused to Glutathione-S-transferase (GST), and extracted. Enzyme activity is then assayed in the presence of the inhibitor BIBW2992, serially diluted in 50% DMSO. A random polymer pEY (4:1) is used as substrate and biotinylated pEY (bio-pEY) is added as a tracer substrate. The kinase domain of HER2 is cloned using the baculovirus system and extracted similarly to that of EGFR kinase. Details of assays for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity are available in Supplementary information.
Cell Research: ^[1]	+ Expand Cell lines: NSCLC cells Concentrations: 0-10 μM Incubation Time: 1 hour Method: 1 × 10⁴ NSCLC cells are transferred into each well of a 96-well plate and cultured overnight in serum-free media for the EGFR phosphorylation assay. After addition of BIBW2992 on the next day, the plates are incubated at 37 °C for 1 hour. EGF-stimulation is done using 100 ng/mL for 10 min at room temperature. Cells are washed with ice cold PBS, extracted with 120 μL HEPEX buffer per well and shaken at room temperature for 1 hour. In all 2 × 10⁴ cells per well is used for the HER2 phosphorylation assay. Streptavidin precoated plates are coated with anti-EGFR-biotin at 1:100 dilution in blocking buffer and c-erb2/HER2 oncoprotein Ab-5(Clone N24)-Biotin. Cell extracts is then transferred to the antibody-coated wells and incubated at room temperature for 1 hour. Extinction is measured at 450 nm. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: Athymic NMRI-nu/nu female mice Formulation: In 0.5% methocellulose-0.4% polysorbate-80 (Tween 80) Dosages: 20 mg/kg Administration: Oral administration (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	97 mg/mL (199.61 mM)
	Ethanol	15 mg/mL (30.86 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Afatinib (BIBW2992) SDF

Molecular Weight	485.94
Formula	C₂₄H₂₅ClFN₅O₃
CAS No.	439081-18-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03711422	Not yet recruiting	Drug: Afatinib	Non-small Cell Lung Cancer\|Leptomeningeal Disease\|Central Nervous System Metastases	National Cancer Centre Singapore	October 2018	Phase 1
NCT03083678	Recruiting	Drug: Afatinib	Chordoma	Leiden University Medical Center\|Chordoma Foundation\|Boehringer Ingelheim	June 21 2018	Phase 2
NCT03370770	Active not recruiting	Drug: Afatinib\|Drug: Osimertinib	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	December 28 2017	--
NCT02423525	Recruiting	Drug: Afatinib	Brain Cancer	Santosh Kesari\|Boehringer Ingelheim\|John Wayne Cancer Institute	December 2016	Phase 1
NCT02695290	Terminated	Drug: Afatinib	Carcinoma Non-Small-Cell Lung\|ErbB Receptors	Boehringer Ingelheim	March 17 2016	Phase 4
NCT02171741	Completed	Drug: BIBW 2992\|Drug: Docetaxel	Neoplasms	Boehringer Ingelheim	April 2005	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
For in vivo experiment of afatinib, we recommend 0.5% methylcellulose/0.2% Tween 80 as vehicle.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Selective EGFR Inhibitor

Erlotinib HCl (OSI-744) : EGFR-selective, IC50=2 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.
Classic EGFR Inhibitor

WZ4002 : Mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.

Related EGFR Products

Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686, AVL-301)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Choose Your Country or Region

By Signaling Pathways

By product type

Afatinib (BIBW2992)

Cited by 98 Publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Afatinib (BIBW2992) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products

Choose Your Country or Region

By Signaling Pathways

By product type

Afatinib (BIBW2992)

Cited by 98 Publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Afatinib (BIBW2992) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)